Restructuring efforts and Lyme vaccine regulatory timeline take center stage.

Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The vaccine filing follows late stage clinical results that reported encouraging efficacy and safety in preventing Lyme disease. A recent patent report highlighted Pfizer as a leading holder of next generation antibody drug conjugate intellectual property in cancer treatment. For readers looking...

Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With fresh product news and shifting expectations around its portfolio, investors are weighing whether the recent rebound leaves enough room for attractive long term returns. The share price is down about 28% over five years. This points to a company that has yet to fully reward long term holders...

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a

Consumer spending fell in July while Middle East hostilities weigh on risk appetite, today, Aug. 14, 2026.

The European Medicines Agency validated the marketing authorization application for Valneva’s Lyme disease vaccine, which it developed with Pfizer

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

Valneva SE (INRLF) navigates a transitional first half with a strong cash position and a clear focus on its pipeline, as it reaffirms full-year guidance despite a significant operating loss.

Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac

Valneva SE (INRLF) showcases strong vaccine progress but faces hurdles with declining sales and operational losses.

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous